Y. Lynn Wang

About

Fox Chase Cancer Center: Philadelphia, PA, US

Employment

• Fox Chase Cancer Center Professor
  2018 - Present
• University of Chicago Comprehensive Cancer Center Member
  2014 - Present
• University of Chicago Medical Center Attending Molecular Pathologist
  2013 - Present
• University of Chicago Professor
  2013 - Present
• Joan and Sanford I Weill Medical College of Cornell University Associate Professor
  2008 - 2013
• New York-Presbyterian Hospital Associate Attending Pathologist
  2008 - 2013

Education

• State University of New York MD
  ? - 2002
• Brandeis University PhD
  ? - 1995
• Peking University Health Science Centre MD
  ? - 1988

Projects & Funding

Projects & funding information is unavailable.

Publications (109)

• SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker
  Oncogene 2023 DOI: 10.1038/s41388-022-02565-7
  +Save
• Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
  British Journal of Haematology 2023 DOI: 10.1111/bjh.18418
  +Save
• Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
  Blood Cancer Journal 2021 DOI: 10.1038/S41408-021-00429-Z
  +Save
• Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2
  Blood Advances 2021 DOI: 10.1182/BLOODADVANCES.2020001665
  +Save
• SHP1 Loss Augments DLBCL Cellular Response to Ibrutinib: A Candidate Predictive Biomarker
  Blood 2021 DOI: 10.1182/BLOOD-2021-146086
  +Save
• Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia
  The Journal of Molecular Diagnostics 2020 DOI: 10.1016/j.jmoldx.2020.06.004
  +Save
• Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed/refractory b-cell malignancies
  Clinical Cancer Research 2019 DOI: 10.1158/1078-0432.CCR-18-1047
  +Save
• Metabolic detection of Bruton's tyrosine kinase inhibition in mantle cell lymphoma cells
  Molecular Cancer Research 2019 DOI: 10.1158/1541-7786.MCR-18-0256
  +Save
• Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma
  Blood Advances 2018 DOI: 10.1182/bloodadvances.2018016048
  +Save
• Erratum: Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma (Blood Advances (2018) 2:16 (2039-2051) DOI: 10.1182/bloodadvances.201801604)
  Blood Advances 2018 DOI: 10.1182/bloodadvances.2018026344
  +Save